Evolving therapeutic landscape of advanced hepatocellular carcinoma
C Yang, H Zhang, L Zhang, AX Zhu… - Nature reviews …, 2023 - nature.com
Hepatocellular carcinoma (HCC) is one of the most common solid malignancies worldwide.
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
A large proportion of patients with HCC are diagnosed at advanced stages and are only …
[HTML][HTML] Regulated cell death (RCD) in cancer: key pathways and targeted therapies
F Peng, M Liao, R Qin, S Zhu, C Peng, L Fu… - Signal transduction and …, 2022 - nature.com
Regulated cell death (RCD), also well-known as programmed cell death (PCD), refers to the
form of cell death that can be regulated by a variety of biomacromolecules, which is …
form of cell death that can be regulated by a variety of biomacromolecules, which is …
[HTML][HTML] Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
U Anand, A Dey, AKS Chandel, R Sanyal, A Mishra… - Genes & …, 2023 - Elsevier
Cancer is an abnormal state of cells where they undergo uncontrolled proliferation and
produce aggressive malignancies that causes millions of deaths every year. With the new …
produce aggressive malignancies that causes millions of deaths every year. With the new …
Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
[HTML][HTML] PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance
The Poly (ADP-ribose) polymerase (PARP) family has many essential functions in cellular
processes, including the regulation of transcription, apoptosis and the DNA damage …
processes, including the regulation of transcription, apoptosis and the DNA damage …
[HTML][HTML] Breast cancer treatments: updates and new challenges
A Burguin, C Diorio, F Durocher - Journal of personalized medicine, 2021 - mdpi.com
Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …
Poly (ADP-ribose) polymerase inhibition: past, present and future
The process of poly (ADP-ribosyl) ation and the major enzyme that catalyses this reaction,
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
poly (ADP-ribose) polymerase 1 (PARP1), were discovered more than 50 years ago. Since …
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
Background Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers with
defects in homologous recombination repair by synthetic lethality. New therapies are …
defects in homologous recombination repair by synthetic lethality. New therapies are …
Olaparib for metastatic castration-resistant prostate cancer
Background Multiple loss-of-function alterations in genes that are involved in DNA repair,
including homologous recombination repair, are associated with response to poly …
including homologous recombination repair, are associated with response to poly …
[HTML][HTML] Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised …
Background Metastatic castration-resistant prostate cancer is enriched in DNA damage
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …
response (DDR) gene aberrations. The TOPARP-B trial aims to prospectively validate the …